Patents by Inventor Wolfgang Guba

Wolfgang Guba has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyridyl-triazabicycles
    Patent number: 10047102
    Abstract: The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: August 14, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Andreas Kuglstatter, Ulrike Obst Sander, Jens-Uwe Peters, Mark Rogers-Evans, Thomas Woltering, Christian Schnider, Roger Wermuth
  • BACE1 inhibitors
    Patent number: 10047081
    Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: August 14, 2018
    Assignee: Hoffman-La Roche Inc.
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Jens-Uwe Peters, Thomas Woltering
  • PYRIDYL-TRIAZABICYCLES
    Publication number: 20180194779
    Abstract: The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Application
    Filed: July 21, 2015
    Publication date: July 12, 2018
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Andreas Kuglstatter, Ulrike Obst Sander, Jens-Uwe Peters, Mark Rogers-Evans, Thomas Woltering, Christian Schnider, Roger Wermuth
  • ETHYNYL DERIVATIVES
    Publication number: 20180134721
    Abstract: The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
    Type: Application
    Filed: January 12, 2018
    Publication date: May 17, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Lothar Lindemann, Fionn O'Hara, Antonio Ricci, Daniel Rueher, Eric Vieira
  • BACE1 inhibitors
    Patent number: 9920072
    Abstract: The present invention provides a compound of formula (I), having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: March 20, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Jens-Uwe Peters, Mark Rogers-Evans, Didier Rombach, Thomas Woltering
  • BACE1 INHIBITORS
    Publication number: 20180057485
    Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Application
    Filed: March 16, 2016
    Publication date: March 1, 2018
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Jens-Uwe Peters, Thomas Woltering
  • 2,2,2-trifluoroethyl-thiadiazines
    Patent number: 9896438
    Abstract: The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: February 20, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Lilli Anselm, Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Haap Wolfgang, Jens-Uwe Peters, Thomas Woltering, Ulrike Obst Sander, Mark Rogers-Evans
  • ETHYNYL DERIVATIVES
    Publication number: 20180002333
    Abstract: The present invention relates to compounds that may be used for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
    Type: Application
    Filed: September 18, 2017
    Publication date: January 4, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Barbara BIEMANS, Wolfgang Guba, Georg Jaeschke, Jean-Marc Plancher, Antonio Ricci, Daniel Rueher, Eric Vieira, Fionn O'Hara
  • BACE1 INHIBITORS
    Publication number: 20170334930
    Abstract: The present invention provides a compound of formula (I), having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Application
    Filed: October 30, 2015
    Publication date: November 23, 2017
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Jens-Uwe Peters, Mark Rogers-Evans, Didier Rombach, Thomas Woltering
  • 2,2,2-TRIFLUOROETHYL-THIADIAZINES
    Publication number: 20170226091
    Abstract: The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Application
    Filed: August 12, 2015
    Publication date: August 10, 2017
    Inventors: Lilli ANSLEM, Bjoern BARTELS, Cosimo DOLENTE, Wolfgang GUBA, Haap WOLFGANG, Jens-Uwe PETERS, Thomas WOLTERING, Ulrike OOBST SANDER, Mark ROGERS-EVANS
  • Ethynyl derivatives
    Patent number: 9725416
    Abstract: The present invention relates to compounds that may be used in the treatment or prevention of disorders relating to allosteric modulation of the mGluR4 receptor. Such compounds may be used for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: August 8, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Eric Vieira, Georg Jaeschke, Wolfgang Guba, Antonio Ricci, Daniel Rueher, Barbara Biemans, Jean-Marc Plancher, Fionn O'Hara
  • Ethynyl derivatives
    Patent number: 9695128
    Abstract: The present invention relates to compounds of formula I having variables as described herein, which are useful for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: July 4, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Antonio Ricci, Daniel Rueher, Eric Vieira
  • Ethynyl derivatives
    Patent number: 9676732
    Abstract: It has been surprisingly been found that the compounds of general formula I are positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4), useful for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: June 13, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Antonio Ricci, Daniel Rueher, Eric Vieira
  • ETHYNYL DERIVATIVES
    Publication number: 20170114028
    Abstract: It has been surprisingly been found that the compounds of general formula I are positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4), useful for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
    Type: Application
    Filed: September 30, 2016
    Publication date: April 27, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Antonio Ricci, Daniel Rueher, Eric Vieira
  • 5-aryl-1-imino-1-oxo-[1,2,4]thiadiazines
    Patent number: 9605006
    Abstract: The present invention provides a compound of formula I? having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: March 28, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Wolfgang Guba, Wolfgang Haap, Andreas Kuglstatter, Jens-Uwe Peters, Ulrike Obst Sander, Christian Schnider, Roger Wermuth, Thomas Woltering
  • ETHYNYL DERIVATIVES
    Publication number: 20170008854
    Abstract: The present invention relates to compounds useful for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
    Type: Application
    Filed: July 8, 2016
    Publication date: January 12, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Antonio Ricci, Daniel Rueher, Eric Vieira
  • BACE1 inhibitors
    Patent number: 9540397
    Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: January 10, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bjoern Bartels, Philipp Cueni, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Andreas Kuglstatter, Ulrike Obst Sander, Jens-Uwe Peters, Mark Rogers-Evans, Walter Vifian, Thomas Woltering
  • ETHYNYL DERIVATIVES
    Publication number: 20160362383
    Abstract: The present invention relates to compounds that may be used in the treatment or prevention of disorders relating to allosteric modulation of the mGluR4 receptor. Such compounds may be used for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
    Type: Application
    Filed: August 24, 2016
    Publication date: December 15, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Eric Vieira, Georg Jaeschke, Wolfgang Guba, Antonio Ricci, Daniel Rueher, Barbara Biemans, Jean-Marc Plancher, Fionn O'Hara
  • 5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES
    Publication number: 20160318952
    Abstract: The present invention provides a compound of formula I? having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Application
    Filed: December 17, 2014
    Publication date: November 3, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Wolfgang Guba, Wolfgang Haap, Andreas Kuglstatter, Jens-Uwe Peters, Ulrike Obst Sander, Christian Schnider, Roger Wermuth, Thomas Woltering
  • ETHYNYL DERIVATIVES
    Publication number: 20160207890
    Abstract: It has been surprisingly been found that the compounds of general formula I are positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4), useful for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
    Type: Application
    Filed: March 25, 2016
    Publication date: July 21, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Barbara BIEMANS, Wolfgang GUBA, Georg JAESCHKE, Antonio RICCI, Daniel RUEHER, Eric VIEIRA